DENNIS WEISSMAN & ASSOCIATES, LLC
Dennis Weissman is a widely respected independent healthcare analyst, consultant and thought leader who has worked in the clinical laboratory and anatomic pathology sectors for over three decades.
Strategic market intelligence
M&A Advisory Services
Public Policy Advice
Having founded a national information company focusing on the diagnostic industry, Dennis is now actively engaged in providing M&A advisory services for lab and AP organizations.
He serves in an advisory role with a variety of diagnostic companies and remains a popular conference and workshop speaker before state, regional and national healthcare organizations.
Mr Weissman serves on the Viewics’ Advisory Board which advises the company on its business intelligence and analytics solution products which enable healthcare organizations to enhance their operational, clinical and financial outcomes. In addition, he provides guidance on strategic issues and raising awareness of industry direction and trends.
Mr. Weissman serves as a expert healthcare consultant for the primary research and knowledge firm that operates a membership-based platform of subject matter experts who provide independent ad-hoc consulting services to companies around the world.
Mr. Weissman serves as an expert instructor on federal regulations affecting healthcare providers and suppliers with emphasis on Medicare and OIG requirements and how to ensure compliance.
Healthcare Industry Consultant
A nationally known, independent analyst, consultant and thought leader for the clinical laboratory and anatomic pathology sectors for over three decades, Dennis is President of Dennis Weissman & Associates, LLC, Falls Church, VA, a consultancy which provides market intelligence, M&A advisory services, business leadership and public policy advice to diagnostic and life science companies and organizations. Mr. Weissman has expertise in Medicare and health care reform policies and trends; clinical laboratory and pathology payment & compliance policies as well as business trends affecting the diagnostic sector.
He currently advises BroadOak Capital Advisors, Bethesda, MD. an investment bank with a comprehensive focus on the life sciences industry. In addition, he is on the advisory board of Viewics, Inc., Sunnyvale, CA, an analytics platform for healthcare organizations. In 1979, he founded and served as publisher of Washington G-2 Reports (now G2 Intelligence), an information company that reports on and analyzes the U.S. clinical laboratory industry via newsletters, research reports and conferences which was sold in 1999 to IOMA, a subsidiary of BNA.
Prior to G2, he served as the Director of the Washington Office of the American Society for Medical Technology (now ASCLS) for five years and as Special Assistant to the Deputy Assistant Secretary for Health, Department of Health, Education & Welfare (now HHS) for two years.
Mr. Weissman holds a BA degree in political science from the State University of New York at Buffalo and a MS degree in counseling and higher education administration from Indiana University, Bloomington, IN.
Clinical Laboratory Industry News
What’s the bottom-line for labs? About three quarters of all test codes on the revised CLFS would have their payment amounts reduced under the weighted median of private payor rates while a mere 10% would be raised. Even worst for labs, the preliminary market-based CLFS rates would result in a cumulative reduction averaging roughly 35% for the majority of high volume tests over the next few years. These cuts will be phased in, with a maximum 10% per year for each of the first three years (2018-2020) and no more than a 15% cut per year for the following three years (2021-2023).read more